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Abstract
Background
Despite substantial falls in coronary heart disease (CHD) mortality in the United Kingdom
(UK), marked socioeconomic inequalities in CHD risk factors and CHD mortality persist. We
investigated whether inequity in CHD healthcare in Wales (UK) could contribute to the
observed social gradient in CHD mortality.
Methods and findings
Linking data from primary and secondary care we constructed an electronic cohort of indivi-
duals (n = 1199342) with six year follow-up, 2004–2010. We identified indications for recom-
mended CHD interventions, measured time to their delivery, and estimated risk of receiving
the interventions for each of five ordered deprivation groups using a time-to-event approach
with Cox regression frailty models. Interventions in primary and secondary prevention in-
cluded risk-factor measurement, smoking management, statins and antihypertensive therapy,
and in established CHD included medication and revascularization. For primary prevention,
five of the 11 models favoured the more deprived and one favoured the less deprived. For
medication in secondary prevention and established CHD, one of the 15 models favoured the
more deprived and one the less deprived. In relation to revascularization, six of the 12 models
favoured the less deprived and none favoured the more deprived–this evidence of inequity
exemplified by a hazard ratio for revascularization in stable angina of 0.79 (95% confidence
interval 0.68, 0.92). The main study limitation is the possibility of under-ascertainment or mis-
classification of clinical indications and treatment from variability in coding.
Conclusions
Primary care components of CHD healthcare were equitably delivered. Evidence of inequity
was found for revascularization procedures, although this inequity is likely to have only a
modest effect on social gradients in CHD mortality. Policymakers should focus on reducing
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Data Availability Statement: The data used in this
study are available in the SAIL databank at
Swansea University, Swansea, UK. All proposals to
use SAIL data are subject to review by an
independent Information Governance Review Panel
(IGRP). Before any data can be accessed, approval
must be given by the IGRP. The IGRP gives careful
consideration to each project to ensure proper and
appropriate use of SAIL data. When access has
been granted, it is gained through a privacy-
protecting safe haven and remote access system
referred to as the SAIL Gateway. SAIL has
inequalities in CHD risk factors, particularly smoking, as these, rather than inequity in health-
care, are likely to be key drivers of inequalities in CHD mortality.
Introduction
Coronary heart disease (CHD) mortality rates have declined rapidly in recent decades in most
middle- to high-income countries [1,2,3]. However a steep social gradient in age-adjusted
CHD mortality persists [1,4]. In the UK the rate ratio for premature CHD death in men was
1.84 comparing residents in the most and least deprived quintiles in 2008 [1] and the decline
in CHD mortality in England (1982–2006) was faster in the least deprived areas [5]. Marked
socioeconomic inequalities in major risk factors for CHD have been found in the UK [6,7, 8]
but it is not clear whether these inequalities fully explain the mortality gradient, as inequity
(inequality to the disadvantage of more deprived groups) in provision of or access to health-
care might contribute to the gradient.
Modelling studies of UK populations have estimated that the decline in CHD mortality has
been largely due to population-level reduction in risk factors, particularly rates of smoking and
levels of blood pressure and cholesterol. [9–12]. The IMPACT studies, which estimated the
proportions of the fall in CHD mortality attributable to changes in risk factors or treatments
(effectiveness and provision) suggest that in England and Wales, between 1981 and 2000, 58%
of the fall in CHD mortality could be attributed to population-level reduction in major risk
factors and 42% to treatments [9]. An IMPACT study of the period 2000–2007 in England,
during which CHD mortality fell by 36%, estimated that improved uptake of treatments
accounted for approximately 50% of the fall [13].
A number of UK-based ecological studies have reported inequity in use of antihypertensive
medication [14–16] and lipid-lowering medication [17,18] using analysis of practice-level
data. A large individual-level UK study of secondary prevention of CHD found no evidence of
inequity, and some findings suggested that more deprived groups were more likely to receive
treatment [19]. UK-based individual-level studies of the management of diabetes found no evi-
dence of inequity in the prescribing of antihypertensive medication and lipid-lowering therapy
[20–22]. Other studies have reported clear evidence of inequity in the use of percutaneous cor-
onary intervention (PCI) and coronary artery bypass grafting (CABG) in the UK [23–29].
A number of studies have examined different components of the CHD healthcare pathway
[13,14,19]. We are not aware of any that examined whether there are inequities across the
entire CHD pathway, from risk assessment, to primary and secondary prevention, medication
in established CHD, and revascularization procedures. This is an important gap in the litera-
ture as the existing studies of different parts of the CHD pathway do not permit strong infer-
ences to be made about the cumulative effect of inequity in one part of the pathway on
inequities that become apparent at a later stage, and do not investigate inequity as a systematic,
whole-pathway phenomenon.
We examined socioeconomic inequalities across a recommended CHD healthcare pathway
in a population-level record-linked cohort study based on primary care, secondary care and
demographic and mortality data from over one million adults, 2004–2010.
The study period followed introduction of the National Service Frameworks (NSF) for Cor-
onary Heart Disease (introduced in 2000 in England and in 2001 in Wales) [30, 31] which set
standards for all aspects of management of CHD, and the period coincided with the Quality
Outcomes Framework (QOF) [32] introduced in 2004 to improve primary care including
CHD healthcare in the UK.
Equity in healthcare for coronary heart disease
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Methods
All analyses were performed within the Secure Anonymized Information Linkage databank
(SAIL) at Swansea University [33,34]. This system allows researchers to link anonymised data,
including routine primary care, hospital activity, mortality and demographic data in a secure
environment. SAIL implements rigorous information governance arrangements involving sys-
tematic data anonymisation, access limitations and disclosure controls. Permission to under-
take the analysis was obtained from the Information Governance Review Panel at SAIL in line
with the Collaborative Review System (project reference number 0156).
Datasets
We defined an electronic cohort of individuals aged 20 or over, resident in Wales and regis-
tered with SAIL-submitting general practices between 1 January 2004 and 31 December 2010.
Routine data from the Welsh Demographic Service, Office of National Statistics (ONS) mortal-
ity files (ICD10 codes for cause of death), Patient Episode Data for Wales (PEDW) hospital
admission data (ICD 10 and Office of Population and Censuses (OPCS) codes for CHD-
related hospital episodes and procedures), and primary care data (Read codes for diagnosis,
investigation and treatment of CHD and for the prescribing of antihypertensive, lipid-lower-
ing and anti-platelet therapy) was extracted to form a linked dataset (for codes see S1 File).
Assessment of socioeconomic inequalities
The Welsh Index of Multiple Deprivation (WIMD) (2008) for the area of residence of the indi-
vidual assessed at the Lower Super Output Area (LSOA) was used as a measure of socioeco-
nomic deprivation. An LSOA is a unit of small-area geography used in the UK with a mean
population of 1500. WIMD 2008 at LSOA level is based on residents’ income, employment sta-
tus, education, housing, health and geographical access to services [35].
Pathway of CHD care
The pathway consisted of a sequence of evidence-based interventions recommended in NSFs
[30, 31] and National Institute for Health and Clinical Excellence (NICE) guidelines [36–40].
These guidelines include CHD risk-assessment, primary prevention, secondary prevention,
and medical and surgical treatment of established disease. The pathway of care investigated is
shown in Fig 1.
Because of the complexity of the clinical algorithms for treating hypertension, the analysis
of this area of the pathway was simplified by considering initiation of treatment as the pre-
scription of any antihypertensive medication.
We identified ‘clinical trigger states’, defined as arising when an individual had an indica-
tion for an intervention according to NICE guidelines. Fig 1 shows the points at which clinical
triggers (along the top of the figure) would be expected to prompt clinical actions (left hand
side of the figure). In our comparisons for revascularization procedures we included a compos-
ite measure that included both PCI and CABG in order to avoid the possibility that increased
use of either procedure might lead to a reduced need for the other procedure.
Covariates. For each clinical trigger identified in an individual, we determined covariates
at the first appearance of the clinical trigger. Covariates available included demographic factors
(age, sex, WIMD 2008); risk-factors (systolic blood pressure (SBP), BMI, smoking status, cho-
lesterol: HDL ratio); co-morbidities based on the Charlson co-morbidity index [41] collapsed
to a binary variable because some components (CHD, cerebrovascular disease and diabetes)
were already considered as covariates; and the Framingham non-laboratory risk assessment
Equity in healthcare for coronary heart disease
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score (comprising sex, age, SBP, BMI, smoking status, reported diabetic status, and current
treatment for hypertension) [42]. To take account of an individual’s previous progress in the
pathway we included covariates for the timing of successive indications for the same interven-
tion (for example high cardiovascular disease risk and subsequent angina both being indica-
tions for lipid-lowering therapy). Thus our models were able to represent an individual’s
cumulative experience in the pathway.
Statistical methods
We used a Cox model with random effects to examine associations with time-to-healthcare
provision, measuring from the initiation of the clinical trigger state to the delivery of the indi-
cated clinical action. We adjusted for important covariates, with the individual’s general prac-
tice or admitting hospital modelled as random effects, to allow for unobserved hospital or GP
specific factors. Modelling was performed using the coxme package in R [43]. For each point
on the pathway we selected covariates on the basis of relevance. Information on the covariates
used in the models is provided in S2 File.
Absolute inequalities were examined by comparing WIMD quintile 5 (most deprived) to
quintile 1 (least deprived). Deprivation quintile (Welsh Index of Multiple Deprivation 2008) of
Fig 1. Clinical triggers and clinical actions investigated in the healthcare pathway for coronary heart disease. Top row shows the
clinical triggers in the healthcare pathway. The left-hand side shows the clinical actions identified in the pathway of care. Where boxes
corresponding to a clinical trigger and clinical action are ticked, equity in the provision of care for that combination of clinical trigger and clinical
action was investigated.
https://doi.org/10.1371/journal.pone.0172618.g001
Equity in healthcare for coronary heart disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0172618 March 16, 2017 4 / 14
residence for the individual was included as a term in every model. We used multiple imputa-
tions with chained equations (MICE) to create five imputed datasets. We imputed all missing
covariates (systolic blood pressure, BMI, cholesterol: HDL ratio, smoking status, admission
specialty, and admission type), using the MICE package in R 2.13.2. [44]. The type 1 error
probability was set to 0.05 for all analyses.
We performed several sensitivity analyses. We re-ran the analyses using the Framingham
1991 risk-assessment tool [45] rather than the non-laboratory tool, the 2001 Townsend depri-
vation index [46] rather than WIMD, and 20 imputations rather than five in the chained equa-
tions for multiple imputation. We also repeated models using a slope index of inequality
across all quintiles, instead of looking at the HR between the most deprived and least deprived
quintiles.
Results
The initial cohort totalled 1201399 but after exclusion of individuals with clearly incorrectly
coded date of birth (202), absent coding for gender (7) or with discontinuous registration with
SAIL (1848) the cohort was reduced to 1199342. The primary care data available for our study
was available only from SAIL-submitting practices and covered approximately 40% of the pop-
ulation of Wales, with a disproportionately high level of coverage in south west Wales. There is
no available evidence that these practices were unrepresentative, and the distribution of urban
and rural residency of the population resembled that of Wales as a whole. Comparing our data
with ONS mid-year data for the whole of Wales, small differences were seen in age distribu-
tion, our cohort having 1.2% fewer in the proportion aged over 40.
The clinical triggers and related clinical actions are summarized in Table 1.
Fig 2 shows the hazard ratio for the most deprived compared with the least deprived quin-
tile (with 95% confidence intervals) for socioeconomic inequalities across the pathway of CHD
healthcare.
Management of risk-factors
The clinical trigger, based on NSF and NICE guidance, for CHD risk-factor assessment was
that the individual was aged 40 or over and was not previously recognized as being at high
CHD risk. Three of the five comparisons showed components of CHD risk-assessment that
favoured the most deprived quintile: ascertainment of smoking status, HR 1.20 (95% CI 1.17–
1.24), BMI ascertainment, HR 1.12 (95% CI 1.08–1.16), measurement of BP, HR 1.03 (95% CI
1.00–1.06). The recording of a full risk-profile favoured the least deprived quintile, HR 0.97
(95% CI 0.95–1.00).
Provision of smoking-cessation advice favoured the most deprived group, HR 1.1 (95% CI
1.06–1.14).
Use of antihypertensive medication in individuals with raised systolic blood pressure (three
readings above 160 mm Hg [38]) but otherwise at low risk, favoured the most deprived group,
HR 1.22 (95% CI 1.13–1.31).
Medication in established disease
Use of statins in individuals with stable angina favoured the least deprived, HR 0.87 (95%
CI 0.78–0.97). Use of aspirin in individuals with unstable angina favoured the most deprived,
HR 1.24 (95% CI 1.05–1.46). The other 13 comparisons showed no statistically significant
differences.
Equity in healthcare for coronary heart disease
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Table 1. Numbers of clinical triggers and associated clinical actions at different positions in the pathway of care for coronary heart disease.
Pathway
position
Clinical trigger Clinical action Number of clinical
triggers
Number of clinical
actions
1 Aged 40+ with no high risk
diagnosis
Ascertainment of smoking status 122486 72291
2 Aged 40+ with no high risk
diagnosis
Measurement of BMI 122486 46235
3 Aged 40+ with no high risk
diagnosis
Measurement of BP 122486 64312
4 Aged 40+ with no high risk
diagnosis
Measurement of cholesterol 122486 28652
5 Aged 40+ with no high risk
diagnosis
Full cardiovascular risk assessment 122486 84969
6 First identified as smoker Referral to smoking-cessation services 55161 2514
7 First identified as smoker Provision of smoking-cessation advice 55161 45926
8 BP raised and low-risk Treatment with antihypertensive
medication
13814 9899
9 BP raised and high-risk Treatment with antihypertensive
medication
106079 75797
10 Risk assessed high Statin 105301 20661
11 High-risk diagnosis Statin 34387 19389
12 Stable angina Statin 11104 4660
13 Stable angina and diabetes Statin 2457 968
14 Unstable angina Statin 4462 2178
15 MI Statin 10442 5372
16 Stable angina Aspirin 9433 3923
17 Stable angina and diabetes Aspirin 2736 919
18 Unstable angina Aspirin 4172 2041
19 Stable angina Statin 11104 4660
20 Stable angina and diabetes ACE inhibitor 3361 1092
21 Unstable angina ACE inhibitor 5287 1967
22 MI ACE inhibitor 10595 5270
23 Unstable angina Beta-blocker 10405 285
24 MI Beta-blocker 16639 363
25 Unstable angina Clopidogrel 13907 5783
26 MI Clopidogrel 20467 10132
27 Stable angina PCI 18934 1172
28 Stable angina and diabetes PCI 8956 300
29 Unstable angina PCI 13907 2130
30 MI PCI 20467 5118
31 Stable angina CABG 18934 1150
32 Stable angina and diabetes CABG 8956 385
33 Unstable angina CABG 13907 1155
34 MI CABG 20467 1645
35 Stable angina Revascularisation 18934 2298
36 Stable angina and diabetes Revascularisation 8956 676
37 Unstable angina Revascularisation 13907 3230
38 MI Revascularisation 20467 6649
https://doi.org/10.1371/journal.pone.0172618.t001
Equity in healthcare for coronary heart disease
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Fig 2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between absolute socioeconomic inequalities and
provision of healthcare for or coronary heart disease. Where the association is not statistically significant at the p<0.05 level the box is
Equity in healthcare for coronary heart disease
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Revascularization
Of the 12 comparisons made in relation to revascularization procedures six favoured the least
deprived, and six showed no significant difference although favouring at a non-significant
level the least deprived. In individuals with stable angina the HR for PCI was 0.72 (95% CI
0.59–0.88) and for revascularization (combined) 0.79 (95% CI 0.68–0.92). In unstable angina
the HR for PCI was 0.76 (95% CI 0.66–0.88) and for revascularization (combined) 0.83 (95%
CI 0.74–0.94). In myocardial infraction (MI) the HR for PCI was 0.83 (95% CI 0.75–0.92) and
for revascularization (combined) 0.83 (95% CI 0.77–0.91).
Sensitivity analyses
Sensitivity analyses, using the Framingham 1991 risk-assessment tool rather than the non-lab-
oratory tool, the 2001 Townsend deprivation quintiles rather than WIMD (2005), 20 imputa-
tions in the chained equations for multiple imputations, and using a slope-index-of-equality
(instead of looking at the HR for the most deprived compared to least deprived deprivation
quintile) all had little effect on the overall pattern of our findings.
Discussion
Main findings
For the healthcare pathway (excluding the composite revascularisation outcome), we found six
points in the pathway where the most deprived quintile were more likely to receive the clinical
action in question and five points where the least deprived were more likely to receive the clin-
ical action; at 23 points there was no significant difference. Our interpretation of these findings
was that, in a population-level analysis of the entire CHD healthcare pathway, there was no evi-
dence of systematic inequity in utilisation of healthcare adjusted for need.
The study was not designed to identify inequity at specific points in the pathway, and,
with the problem of multiple comparison in mind, interpretation of findings at specific stages in
the pathway needs to be undertaken with caution. We did identify evidence that pattern of the
inequalities related to the stages of the pathway. For primary prevention, significant inequalities
favouring the most deprived quintile were found in five of the 11 interventions. Of the 13 in-
terventions for medication in secondary prevention and in established CHD one inequality
favoured the least deprived quintile and one the most deprived. There was evidence of inequality
favouring the least deprived quintile in six of the 12 interventions relating to revascularization.
Comparison with other studies
An individual-level study comprehensively examined prescribing in secondary prevention of
CHD in the UK between 1999 and 2007 and detected no evidence of inequity, its findings sug-
gesting greater prescribing in the most than in the least deprived groups [19]. An IMPACT
modelling study to examine the relationship between socioeconomic status and the factors
that explain the declining rates of CHD mortality in the UK between 2000 and 2007 found no
evidence of inequity in the delivery of a wide range of interventions [13]. Our findings there-
fore broadly concur with those of these studies and a number of other individual-level studies
[20–22] although they conflict with those of several ecological studies [14–18] and studies of
coloured white. For statistically significant results, the box is coloured according to the magnitude of effect on a logarithmic scale; green shading
indicates that the most deprived quintile of the population was more likely to receive the clinical action; red shading indicates that the least
deprived quintile of the population was more likely to receive the clinical action.
https://doi.org/10.1371/journal.pone.0172618.g002
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UK populations during the 1990’s [47–49] that reported evidence of inequity in primary care
elements of CHD healthcare.
Our findings replicate those of a number of studies covering the same time period relating
to revascularization in UK populations, in which rates of revascularization favoured the less
deprived [23–29]. Several studies reporting inequity in revascularization suggest that individu-
als’ attitudes, expectations and consultation thresholds, differing according to socioeconomic
status, may contribute to the inequalities observed [28,50,51]. One qualitative study suggested
that attitudes such as low expectations of treatment and fear of hospitals were more likely to be
found in more deprived groups and formed barriers to referral for angiography and subse-
quent revascularization [52].
Implications for policy
We found that the primary care components of CHD healthcare were delivered equitably in
the population of Wales during the study period 2004–2010. Despite this finding and the
results of comparable studies [13, 19–22], there is evidence that the fall in CHD mortality in
the UK has been faster in more affluent groups and that relative inequality in CHD mortality
has increased [13,53]. Adverse effects of increasing rates of diabetes and obesity are expected
to offset improvements in population risk-profiles [9–12] and, because of higher rates of these
conditions in more deprived groups, to increase relative inequality. These studies suggest that
even if CHD healthcare is equitably delivered, inequalities in CHD outcomes are likely to per-
sist, and relative inequalities to increase, unless inequalities in major risk-factors such as
tobacco use are addressed.
We found clear evidence of inequity in revascularization procedures. Marked increases in
the resources for revascularization, and in the volume of procedures carried out, were observed
in the UK during our study period. Between 2000 and 2012 the rates of PCI (all types) in
Wales increased from 550 per million population to 1363 per million, and between 2004 and
2008 increased from 900 to 1150 per million population. [54]. Our findings suggest that this
increase was not applied equitably. It would be valuable to examine reasons for this, in particu-
lar deprivation-related attitudes (such as low expectations of healthcare and fear of hospitals)
that limit demand, and the distribution of co-morbidities across the social gradient. Comor-
bidities, potentially acting as contraindications to revascularization procedures, may explain
part of the observed inequality, and in our study the evidence of inequity weakened when the
model was adjusted for comorbidities.
Evidence from modelling studies helps to clarify the potential effect on CHD mortality of
the observed inequity in revascularization. In England and Wales between 1981 and 2000,
while 42% of the decline in CHD mortality was due to medical and surgical intervention, only
3.8% of deaths prevented or postponed (DPP) were due to CABG or angioplasty [9]. This esti-
mate is similar to that reported in a comparable USA study [55]. In a study of USA cardiac
patients (1980–2000) it was estimated that less than 6% of total life-years gained were attribut-
able to revascularization procedures [56]. In a study of declining CHD mortality in New Zea-
land 1983–1993 [57] DPP by revascularization procedures were estimated to contribute 5% of
the total CHD mortality reduction. A study using IMPACT modelling to explain the decline in
CHD mortality in Northern Ireland between 1987 and 2007, calculated that CABG or angio-
plasty in acute MI or unstable angina accounted for less than 1% of DPP [11]. We assess from
such estimates that the degree of inequity that we observed in revascularization procedures
would make only a small contribution to the steep social gradient of CHD mortality (hazard
ratio 1.72 in our adjusted model). Further work to monitor inequalities in revascularization
and to quantify their effects on mortality, would be valuable to policy-makers.
Equity in healthcare for coronary heart disease
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Strengths of the study
We based our study on data from a large number of individuals (more than one million) and
identified a large number of clinical triggers for each of which we determined the time to clini-
cal action. In contrast to previous studies that had examined different parts of CHD risk-factor
assessment, management and treatments, we were able to examine inequalities across an entire
recommended CHD pathway at the individual level. We were able to use a hierarchical struc-
ture (individual/practice/hospital) in our modelling and this allowed us to take account of sup-
ply-side factors as random variables. By using a time-to-event approach we eliminated in our
analysis the use of an arbitrary standard for acceptable time-intervals between clinical trigger
and action.
We used a set of algorithms for identifying, collecting and classifying relevant information
on clinical triggers from a large and unrefined data source. Information on the length of time
for which a particular clinical action was indicated and the number of different previous indi-
cations that had arisen for that action, enabled us to adjust for elements in an individual’s his-
tory as potential confounders in models.
This methodology may be applicable to studies of pathways of care for diseases other than
CHD.
Limitations
The main study limitation is that inaccuracies and variability in the use of Read and ICD codes
in medical records are known to occur [58,59]. Under-ascertainment or misclassification of
clinical indications and interventions would tend to bias the results towards null, potentially
reducing the power of our study to identify genuine inequity.
Prescribing data relating to inpatient treatment of acute coronary syndromes was not
available in our routine data and we therefore had information on drug treatments for
individuals only after they had left hospital. We did not to include anti-anginal therapy in
the pathway as it is not considered directly to affect CHD mortality, and because our data
would not necessarily allow us to distinguish whether some types of medication, including
calcium channel blockers and beta blockers, were used in an individual to treat angina or
hypertension.
Our study examined a health service in which healthcare is free at the point of delivery and
there is no charge for prescriptions. The system of healthcare in the UK, in which interventions
such as QOF can operate, contrasts with less integrated systems such as those in the USA, and
further work using a similar approach in such health systems without might be revealing.
Conclusions and recommendations
Primary care components of CHD healthcare were equitably delivered in the population of
Wales between 2004 and 2011. Clear evidence of inequity was found in relation to revasculari-
zation procedures.
Organisations and policymakers should focus on the clear social gradients in risk factors as
it is these, rather than inequity in healthcare, that are the key drivers of social gradients in
CHD mortality. They should address the increasing rates of obesity and diabetes that are off-
setting the benefits of recent reductions in other major CHD risk factors such as smoking.
The time-to-event methodology of this study has been shown to be an effective way of
examining evidence of equity in utilization of healthcare and could be similarly used in studies
of other disease areas.
Equity in healthcare for coronary heart disease
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